Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tenofovir disoproxil fumarate

Gilead Sciences promotes Dr Alessandro Riva to EVP, oncology therapeutics

He's been with the firm since January, when he joined from Novartis

Gilead Sciences

People at-risk of HIV in England could get PrEP from September

10,000 people will use Gilead’s Truvada in the upcoming trial

- PMLiVE

Not dying of ignorance – 30 years on

Behavioural changes with HIV and AIDS

- PMLiVE

Aids related deaths almost halved since 2005, says UNAIDS

And 53% of people living with HIV now have access to treatment

- PMLiVE

GSK’s pipeline cull claims sirukumab, and possibly rare disease unit

Makeover designed to deliver a leaner, fitter company in 2020

- PMLiVE

ViiV files two-drug HIV maintenance regimen

SWORD studies show treatment could maintain viral suppression

- PMLiVE

Gilead plans fightback against HIV arch-rival ViiV

Descovy sees phase III success after the TAF-based drug proves non-inferior to Triumeq

EU flag

EU starts investigation of Aspen’s cancer drug pricing

Amid reports of price increases of several hundred per cent

- PMLiVE

Gilead Sciences appoints general manager, Canada

Nordics general manager Kennet Brysting moves to take up new post

Sanofi reception

Sanofi wins EU approval for new diabetes combination Suliqua

European Commission licenses the once-daily version of Lantus and Lyxumia

- PMLiVE

Gilead’s Hepatitis B therapy Vemlidy granted EU approval

Treatment shows similar efficacy to the firm's Viread at one-tenth of dosage

- PMLiVE

A healthy challenge

The EC’s Dr Vytenis Andriukaitis on Europe’s problems with health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links